Physician profile
Michael C Wallace
NPI 1932192556
$16,443.34
in general payments reported to CMS, 2019-2025
54 companies · $2,543 in 2025
The $2,543 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,403 · 2020: $1,683 · 2021: $1,327 · 2022: $2,306 · 2023: $2,493 · 2024: $2,689 · 2025: $2,543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,692 · Education: $33.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,691.71 |
| Education | $33.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,455.76 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,767.04 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $1,496.76 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $1,231.83 | 2019-2025 | |
| Abbvie INC. | $1,094.60 | 2019-2025 | Qulipta, Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $993.29 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $851.77 | 2019-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $730.07 | 2019-2025 | Jardiance, Synjardy |
| Merck Sharp & Dohme LLC | $581.64 | 2019-2025 | Capvaxive, Belsomra, Gardasil 9 |
| Theratechnologies INC. | $496.55 | 2022-2025 | Trogarzo, Egrifta, Egrifta Sv |
| Abbott Laboratories | $413.48 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Takeda Pharmaceuticals U.S.A., INC. | $411.40 | 2019-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $330.89 | 2022-2025 | |
| Gilead Sciences, INC. | $328.41 | 2019-2024 | |
| Amarin Pharma, INC. | $263.88 | 2019-2023 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.